By Cara Mannion ( January 11, 2017, 1:37 PM EST) -- A cancer therapy developer led shareholders to believe testing for its new leukemia treatment drug was going smoothly despite the U.S. Food and Drug Administration's concerns that the drug causes liver damage, leading to decreased share values, a putative class alleged in Washington federal court Tuesday....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.